125iodine reimplantation for locally progressive prostatic carcinoma.
We treated 13 patients with a second 125iodine implant for local recurrence of prostatic carcinoma. All patients had biopsy proved palpable recurrence without evidence of distant metastases. Full doses of irradiation were used (median matched peripheral dose 170 Gy.). Six patients had complete regression of palpable recurrence, 2 had partial regression, 2 had no apparent response and 3 were unevaluable for local response. Actuarial freedom from local disease progression at 5 years was 51%. Despite a relatively high rate of local disease control the actuarial rate of distant metastases reached 100% at 6 years after reimplantation. There were 2 severe rectal complications and 4 instances of mild to moderate urinary incontinence among the 13 patients. Local regression of recurrent prostatic carcinoma may be achieved with 125iodine reimplantation but most patients still had distant metastases.
Wallner
K E
KE
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
Nori
D
D
Morse
M J
MJ
Sogani
P C
PC
Whitmore
W F
WF
Fuks
Z
Z
D001918:Brachytherapy; D002277:Carcinoma / Q000532:radiotherapy*; D005500:Follow-Up Studies; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000532:radiotherapy*; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D013997:Time Factors
D007457:Iodine Radioisotopes